FDA Expands Ibrutinib Use in Chronic Lymphocytic Leukemia

Share this content:
People with chronic lymphocytic leukemia and 17p deletion can now get the therapy.
People with chronic lymphocytic leukemia and 17p deletion can now get the therapy.

Approved use for Imbruvica (ibrutinib) has been expanded to include people with chronic lymphocytic leukemia (CLL) who have a deletion in chromosome 17, the U.S. Food and Drug Administration said Monday in a news release.

People with the 17p deletion are prone to a poor response to standard therapies for CLL, the agency noted. Almost 16,000 Americans will be diagnosed with CLL and 4,600 will die from it this year, the FDA said, citing projections from the U.S. National Cancer Institute.

RELATED: Ibrutinib 'Effective New Single-agent Therapy' for Relapsed/Refractory CLL

The expanded approval followed a clinical study of 391 people, 127 of whom had the 17p deletion. The trial was stopped early after participants treated with Imbruvica showed a 78 percent reduction in risk of disease progression or death, the FDA said. The most common side effects reported were a decrease in white blood cells, diarrhea, anemia, fatigue, muscle and bone pain, upper respiratory tract infection, rash, nausea, and fever.

Imbruvica was approved in November 2013 to treat mantle cell lymphoma among people who had been given at least one prior therapy. The drug is co-marketed by Sunnyvale, Calif.-based Pharmacyclics and Horsham, Penn.-based Janssen Biotech.

  1. FDA News Release. "FDA approves Imbruvica to treat chronic lymphocytic leukemia." July 28, 2014.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs